Blog

Stem Cell Therapy: What Is Approved, What Is Not, and What Is Legitimate

Asare B. Christian, MD, MPH · 2026-11-15

Direct Answer

The only broadly FDA-approved stem cell therapy is hematopoietic stem cell transplantation for specific blood and immune disorders, using bone marrow or cord blood. No stem cell product is approved for arthritis, tendon injury, spinal pain, or aging. Clinics offering those treatments operate outside the approval pathway, sometimes within a regulatory exception and sometimes not.

The Legitimate Core

Hematopoietic stem cell transplantation has decades of evidence behind it and cures or controls a defined list of diseases: leukemias, lymphomas, aplastic anemia, severe immune deficiencies, and certain inherited blood disorders. This is a serious therapy with real risks, including graft-versus-host disease, and its use is restricted to qualified centers.

That is the standard against which everything else should be measured. Not whether stem cells are powerful, but whether a specific product, at a specific dose, in a specific disease, has been shown to help.

How the FDA Regulates This

Cells are regulated as biological drugs under 21 CFR Part 1271. There is an exception, sometimes called the same surgical procedure exception, allowing a surgeon to remove tissue from a patient and reimplant it in the same patient during the same procedure, provided the cells are minimally manipulated and used for their homologous function.

That exception is narrow. Culturing cells for weeks, adding growth factors, or using cells from a donor changes the regulatory status entirely. So does injecting cells into a joint for a purpose different from their normal function.

The practical implication: bone marrow aspirate concentrate used during an orthopedic procedure sits in a different category from cultured mesenchymal stem cells expanded in a laboratory and flown in for injection. Clinics routinely blur that distinction.

What Clinics Commonly Offer

The standard offering is an injection of bone marrow aspirate concentrate, adipose-derived cells, or allogeneic umbilical cord product into a painful joint, tendon, or the spine, sometimes with an accompanying intravenous infusion marketed as anti-aging.

Three issues recur:

Cell dose is unknown. Bone marrow aspirate contains a small fraction of actual stem cells, and the yield varies substantially between patients and techniques. Many clinics do not measure.

The claim outruns the design. Patients are told they are regenerating cartilage or slowing aging. Neither has been demonstrated.

Follow-up is short. Reports of improvement at three months with no control group are testimonials in statistical form.

What the Evidence Actually Shows

Osteoarthritis. Dozens of small trials exist, mostly open-label, mostly small, mostly short. Meta-analyses report modest improvements in pain and function scores, with substantial heterogeneity and high risk of bias. Placebo-controlled trials are rarer and generally show smaller effects. Convincing cartilage regeneration has not been demonstrated in humans.

Ligament and tendon. Case series dominate. The absence of controls makes it impossible to separate treatment effect from the natural course of these injuries, which improves on its own frequently.

Spinal disc injection. Small series report pain improvement. No large controlled trial supports it, and serious complications, including infection and progressive disc injury, are documented.

Aging and frailty. Early-phase trials of intravenous mesenchymal stem cells in frail older adults report acceptable short-term safety and some functional signals in small numbers of patients. No outcome data on mortality, dementia, or long-term function.

What I Would Tell a Patient

If you have knee arthritis and are considering a stem cell injection, ask three questions. What is the measured cell count and viability in what you are injecting into me? What do your own outcome data show at one year in patients like me? And what is the total cost, including the follow-up visits and the second injection that will likely be recommended?

A clinic that cannot answer the first question is selling a procedure, not a therapy. A clinic that cannot answer the second is asking you to fund its data collection without saying so.

Limitations and Honest Uncertainty

The field is not worthless. Cell therapy for musculoskeletal disease is an active area of legitimate research, and specific products with rigorous manufacturing may eventually earn approval for specific indications. The current gap is between biological plausibility and demonstrated clinical benefit, and that gap has been bridged for almost no indication yet.

Frequently Asked Questions

Are stem cell injections for knees FDA approved? No. No marketed stem cell product is approved for knee osteoarthritis.

Is bone marrow aspirate concentrate legal? It can be, under the same surgical procedure exception, when minimally manipulated, used in the same patient at the same procedure for its normal function. Marketing it for regeneration with intravenous add-ons undermines that position.

Stem cells versus PRP? PRP has more controlled trial evidence for knee arthritis than most cell products, and its effect is modest. Neither regrows cartilage.

Can stem cells reverse aging? No human trial has demonstrated that any stem cell intervention slows biological aging or extends life.

References

  1. FDA. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use. Guidance document.
  2. 21 CFR Part 1271.
  3. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813-1826.
  4. Systematic reviews and meta-analyses of mesenchymal stem cell injection for knee osteoarthritis, 2019 to 2024, reporting modest short-term symptom improvements with high heterogeneity.

Educational information only. This is a draft for physician review and is not individualized medical advice.